Cystinuria – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
A rare disorder of renal tubular amino acid transport characterized by the recurrent formation of kidney cystine stones.
Etiology-
Cystinuria
is inherited in an autosomal recessive pattern.
Cystinuria is caused by changes (mutations) in the SLC3A1 and SLC7A9
genes. These genes encode a protein complex that helps control the reabsorption
of amino acids (such as cystine) in the kidneys. Mutations in these genes
disrupt the function of the protein complex, causing cystine to become more
concentrated in the urine.
Epidemiology-
The prevalence of
cystinuria has high ethnographic variation, ranging from 1:2,500 in the Libyan
Jewish population to 1:100,000 in Sweden. The mean global value is estimated at
1:7,000.
The competitive
landscape of Cystinuria includes country-specific approved and pipeline
therapies. Any asset/product-specific designation or review and Accelerated
Approval are tracked and supplemented with analyst commentary.
KOLs
insights of Cystinuria across 8 MM market from the center of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Cystinuria
Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 ADV7103 Advicenne
Pharma Phase 2/3
2 Bucillamine Revive
Therapeutics, Ltd. Phase 2
Comments
Post a Comment